MSCs

Phase 2Small molecule

NNanfang Hospital, Southern Medical University

MSCs is one of 131 small molecule programs targeting Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Multiple System AtrophyActive, not recruiting

PneumoniaPhase 1

Active, not recruiting

Interstitial Lung DiseasePhase 1/Phase 2

Active, not recruiting

Chronic Kidney DiseasePhase 1/Phase 2

Active, not recruiting

Multiple System AtrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

MSCs

NNanfang Hospital, Southern Medical University

Phase 2

1 2

Primaxin

Pfizer

Preclinical

2 3

Jakafi

Incyte

Preclinical

1 4

Avlosulfon

AAlmirall, S.A.

Preclinical

4 5

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Pepcid

KKenvue Brands

Preclinical

1 7

Aciphex

Akero Therapeutics

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Not yet recruiting

Chronic Kidney Disease

NCT07240987

Q1 2031

Phase 2Not yet recruiting

Multiple System Atrophy

NCT07465198

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Mesenchymal Stem Cells for Chronic Kidney Diseases

Not yet recruiting·TThe First Affiliated Hospital of Air Force Medicial University·Phase 1/2·NCT07240987·32 enrolled

Mesenchymal Stem Cells1 trial

Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT02083718·120 enrolled

Multiple System Atrophy1 trial

Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Not yet recruiting·BBiocells Medical·Phase 2·NCT07465198·50 enrolled

Poor Graft Function1 trial

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02240992·120 enrolled

Monoclonal1 trial

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02241018·200 enrolled

6 more indications

Type 1 Diabetic1 trial

MSC Administration for the Management of Type 1 Diabetic Patients

Unknown status·UUniversidad del Desarrollo·Phase 2·NCT02893306·10 enrolled

Interstitial Lung Disease1 trial

MSC for Treatment of Interstitial Lung Disease After Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 1/2·NCT02543073·60 enrolled

Pneumonia1 trial

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19

Unknown status·—·Phase 1·NCT04252118·20 enrolled

Injury1 trial

MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound

Completed·—·Phase 1·NCT02669199·20 enrolled

CMV Infection1 trial

MSC for Treatment of CMV Infection

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT02083731·120 enrolled

aGVHD1 trial

MSC for Severe aGVHD

Unknown status·FFujian Medical University·Phase 2/3·NCT03631589·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for MSCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MSCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MSCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNanfang Hospital, Southern Medical University

MSCs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2031

Trials by Indication[1]

Chronic Kidney Disease1 trial

Mesenchymal Stem Cells1 trial

Multiple System Atrophy1 trial

Poor Graft Function1 trial

Monoclonal1 trial

Type 1 Diabetic1 trial

Interstitial Lung Disease1 trial

Pneumonia1 trial

Injury1 trial

CMV Infection1 trial

aGVHD1 trial

References

Drug Info

Quick Facts

Related News